Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Obesity and metabolic syndrome: potential benefit from specific nutritional components.

Abete I, Goyenechea E, Zulet MA, Martínez JA.

Nutr Metab Cardiovasc Dis. 2011 Sep;21 Suppl 2:B1-15. doi: 10.1016/j.numecd.2011.05.001. Epub 2011 Jul 20. Review.

PMID:
21764273
2.

[Nutrition and metabolic syndrome].

Matía Martín P, Lecumberri Pascual E, Calle Pascual AL.

Rev Esp Salud Publica. 2007 Sep-Oct;81(5):489-505. Review. Spanish.

PMID:
18274353
3.

Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome.

Robinson LE, Buchholz AC, Mazurak VC.

Appl Physiol Nutr Metab. 2007 Dec;32(6):1008-24. Review.

PMID:
18059573
4.

Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors.

Abeywardena MY, Patten GS.

Endocr Metab Immune Disord Drug Targets. 2011 Sep 1;11(3):232-46. Review.

PMID:
21831036
5.

Chronic dietary n-3 PUFA intervention improves dyslipidaemia and subsequent cardiovascular complications in the JCR:LA- cp rat model of the metabolic syndrome.

Lu J, Borthwick F, Hassanali Z, Wang Y, Mangat R, Ruth M, Shi D, Jaeschke A, Russell JC, Field CJ, Proctor SD, Vine DF.

Br J Nutr. 2011 Jun;105(11):1572-82. doi: 10.1017/S0007114510005453. Epub 2011 Jan 31.

PMID:
21276281
6.
7.

n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review.

Nettleton JA, Katz R.

J Am Diet Assoc. 2005 Mar;105(3):428-40. Review.

PMID:
15746832
8.

Dietary treatment of the metabolic syndrome--the optimal diet.

Riccardi G, Rivellese AA.

Br J Nutr. 2000 Mar;83 Suppl 1:S143-8. Review.

PMID:
10889805
9.
10.

Metabolic syndrome: definition and therapeutic implications.

Prasad H, Ryan DA, Celzo MF, Stapleton D.

Postgrad Med. 2012 Jan;124(1):21-30. doi: 10.3810/pgm.2012.01.2514. Review.

PMID:
22314111
11.

Dietary fat, insulin sensitivity and the metabolic syndrome.

Riccardi G, Giacco R, Rivellese AA.

Clin Nutr. 2004 Aug;23(4):447-56. Review.

PMID:
15297079
13.

Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.

Nakajima K.

Curr Clin Pharmacol. 2010 May;5(2):133-9. Review.

PMID:
20156152
14.

Mediterranean diet and metabolic syndrome: the evidence.

Babio N, Bulló M, Salas-Salvadó J.

Public Health Nutr. 2009 Sep;12(9A):1607-17. doi: 10.1017/S1368980009990449. Review.

PMID:
19689829
15.

The metabolic syndrome and its cardiovascular manifestations.

Sánchez-Torres RJ, Delgado-Osorio H.

Bol Asoc Med P R. 2005 Oct-Dec;97(4):271-80. Review.

PMID:
16599068
16.

The metabolic syndrome: definitions, prevalence and management.

Levesque J, Lamarche B.

J Nutrigenet Nutrigenomics. 2008;1(3):100-8. doi: 10.1159/000112457. Epub 2008 Feb 20. Review.

PMID:
19776619
17.

Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study.

Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS.

Circulation. 2007 Mar 27;115(12):1537-43.

18.

Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence.

Lorente-Cebrián S, Costa AG, Navas-Carretero S, Zabala M, Martínez JA, Moreno-Aliaga MJ.

J Physiol Biochem. 2013 Sep;69(3):633-51. doi: 10.1007/s13105-013-0265-4. Epub 2013 Jun 22. Review.

PMID:
23794360
19.

Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.

Fan JG.

J Dig Dis. 2008 May;9(2):63-7. doi: 10.1111/j.1751-2980.2008.00323.x. Review.

PMID:
18419637
20.

Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies.

Fan JG, Peng YD.

Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):572-8. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk